Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1Lymphoma, T-Cell, Peripheral 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 26Paclitaxel 21pembrolizumab 15Radiotherapy 13Carboplatin 13tislelizumab 12Fluorouracil 12Drug Therapy 11Irinotecan 9toripalimab 8Esophagectomy 8Oxaliplatin 6Nivolumab 6Capecitabine 6Neoadjuvant Therapy 5Leucovorin 5Docetaxel 5lenvatinib 4camrelizumab 4Taxes 4Radiation 4Levoleucovorin 4Immune Checkpoint Inhibitors 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4spartalizumab 3sintilimab 3apatinib 3Itraconazole 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × ivarmacitinib × 1 year × Clear all
NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡